WO2001014375A1 - Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives - Google Patents
Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivativesInfo
- Publication number
- WO2001014375A1 WO2001014375A1 PCT/GB2000/003139 GB0003139W WO0114375A1 WO 2001014375 A1 WO2001014375 A1 WO 2001014375A1 GB 0003139 W GB0003139 W GB 0003139W WO 0114375 A1 WO0114375 A1 WO 0114375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulphamoyl
- alkyl
- formula
- pyrid
- compound
- Prior art date
Links
- NBTPFVVASALWCC-UHFFFAOYSA-N C(C1)C11C(C2)(C2CC2)C2CC1 Chemical compound C(C1)C11C(C2)(C2CC2)C2CC1 NBTPFVVASALWCC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/069,019 US6855719B1 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives |
CA002376293A CA2376293A1 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
DE60005850T DE60005850T2 (en) | 1999-08-21 | 2000-08-15 | IMIDAZO [1,2-A] PYRIDINE AND PYRAZOLO [2,3-A] PYRIDINE DERIVATIVES |
EEP200200080A EE04964B1 (en) | 1999-08-21 | 2000-08-15 | Imidazo [1,2a] p ridine and prazolo [2,3a] p ridine derivatives |
MXPA02001674A MXPA02001674A (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2a]pyridine and pyrazolo[2,3a]pyridine derivatives. |
AU65833/00A AU757639B2 (en) | 1999-08-21 | 2000-08-15 | Imidazo(1,2-a)pyridine and pyrazolo(2,3-a)pyridine derivatives |
UA2002032241A UA73522C2 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a]pyridine and pyrazole[2,3-a]pyridine derivatives |
BR0013476-7A BR0013476A (en) | 1999-08-21 | 2000-08-15 | Compound, use thereof, process for preparing a compound, and pharmaceutical composition |
JP2001518706A JP4280442B2 (en) | 1999-08-21 | 2000-08-15 | Imidazo [1,2a] pyridine and pyrazolo [2,3a] pyridine derivatives |
EP00953319A EP1214318B1 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
NZ516740A NZ516740A (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives |
IL14775200A IL147752A0 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives |
AT00953319T ATE251623T1 (en) | 1999-08-21 | 2000-08-15 | IMIDAZO(1,2-A)PYRIDINE AND PYRAZOLO(2,3-A)PYRIDINE DERIVATIVES |
SK240-2002A SK287033B6 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a] pyridine and pyrazo [ 2,3-a] pyridine derivates, method for producing thereof and pharmaceutical composition containing the same |
DK00953319T DK1214318T3 (en) | 1999-08-21 | 2000-08-15 | Imidazo [1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives |
IL147752A IL147752A (en) | 1999-08-21 | 2002-01-21 | 2 - arylaminopyrimidin - 4 - yl imidazo [1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives, their preparation and pharmaceutical compositions containing them |
IS6274A IS2068B (en) | 1999-08-21 | 2002-02-15 | Imidazo [1,2-a] pyridine and pyrazolo [2,3-a] pyridine derivatives |
NO20020832A NO322818B1 (en) | 1999-08-21 | 2002-02-20 | Imidazo (1,2-A) pyridine and pyrazolo (2,3-A) pyridine derivatives, use and preparation thereof, as well as pharmaceutical preparation. |
HK02107002.9A HK1045510B (en) | 1999-08-21 | 2002-09-25 | Imidazo[1 ,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9919778.2A GB9919778D0 (en) | 1999-08-21 | 1999-08-21 | Chemical compounds |
GB9919778.2 | 1999-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001014375A1 true WO2001014375A1 (en) | 2001-03-01 |
Family
ID=10859538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003139 WO2001014375A1 (en) | 1999-08-21 | 2000-08-15 | Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
Country Status (33)
Country | Link |
---|---|
US (1) | US6855719B1 (en) |
EP (1) | EP1214318B1 (en) |
JP (1) | JP4280442B2 (en) |
KR (1) | KR100737259B1 (en) |
CN (1) | CN1174981C (en) |
AR (1) | AR031075A1 (en) |
AT (1) | ATE251623T1 (en) |
AU (1) | AU757639B2 (en) |
BG (1) | BG65566B1 (en) |
BR (1) | BR0013476A (en) |
CA (1) | CA2376293A1 (en) |
CO (1) | CO5460265A1 (en) |
CZ (1) | CZ2002617A3 (en) |
DE (1) | DE60005850T2 (en) |
DK (1) | DK1214318T3 (en) |
EE (1) | EE04964B1 (en) |
ES (1) | ES2208397T3 (en) |
GB (1) | GB9919778D0 (en) |
HK (1) | HK1045510B (en) |
HU (1) | HUP0202494A3 (en) |
IL (2) | IL147752A0 (en) |
IS (1) | IS2068B (en) |
MX (1) | MXPA02001674A (en) |
MY (1) | MY123390A (en) |
NO (1) | NO322818B1 (en) |
NZ (1) | NZ516740A (en) |
PL (1) | PL199615B1 (en) |
PT (1) | PT1214318E (en) |
RU (1) | RU2248976C2 (en) |
SK (1) | SK287033B6 (en) |
UA (1) | UA73522C2 (en) |
WO (1) | WO2001014375A1 (en) |
ZA (1) | ZA200200028B (en) |
Cited By (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016359A1 (en) * | 2000-08-22 | 2002-02-28 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
WO2002066481A1 (en) * | 2001-02-17 | 2002-08-29 | Astrazeneca Ab | Pyrimidine derivatives for inhibition of cell-proliferation |
WO2002066480A2 (en) * | 2001-02-20 | 2002-08-29 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
US6451794B1 (en) | 1997-09-05 | 2002-09-17 | Smithkline Beecham Corporation | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors |
WO2002083675A2 (en) * | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
WO2002096888A1 (en) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
WO2002065979A3 (en) * | 2001-02-20 | 2003-02-20 | Astrazeneca Ab | (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
WO2003031446A1 (en) * | 2001-10-05 | 2003-04-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
WO2003050120A1 (en) * | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
WO2003051886A1 (en) * | 2001-12-17 | 2003-06-26 | Smithkline Beecham Corporation | Pyrazolopyridazine derivatives |
US6593326B1 (en) | 1998-12-24 | 2003-07-15 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
WO2003076433A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | Pyrimidine compounds |
WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
WO2003076435A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | Pyrimidine compounds |
US6632820B1 (en) | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
JP2003532635A (en) * | 2000-02-17 | 2003-11-05 | アムジエン・インコーポレーテツド | Kinase inhibitors |
US6649608B2 (en) | 2000-03-01 | 2003-11-18 | Astrazeneca Ab | 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents |
US6670368B1 (en) | 1999-04-06 | 2003-12-30 | Astrazeneca Ab | Pyrimidine compounds with pharmaceutical activity |
US6710052B2 (en) | 2000-03-01 | 2004-03-23 | Astrazeneca | Pyrimidine compounds |
US6716831B1 (en) | 1999-03-06 | 2004-04-06 | Astrazeneca Ab | 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity |
WO2004033454A1 (en) * | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
US6756498B2 (en) | 2001-04-27 | 2004-06-29 | Smithkline Beecham Corporation | Process for the preparation of chemical compounds |
US6803463B2 (en) | 1999-12-22 | 2004-10-12 | Smithkline Beecham Corporation | Process for the preparation of pyrazolopyridine derivatives |
WO2004101564A1 (en) * | 2003-05-16 | 2004-11-25 | Astrazeneca Ab | Pyrimidine derivatives possessing cell-cycle inhibitory activity |
US6838464B2 (en) | 2000-03-01 | 2005-01-04 | Astrazeneca Ab | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
US6906065B2 (en) | 2000-03-28 | 2005-06-14 | Astrazeneca Ab | 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
US6908920B2 (en) | 2000-07-11 | 2005-06-21 | Astrazeneca Ab | Pyrimidine derivatives |
US6919352B2 (en) | 2000-12-15 | 2005-07-19 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
JP2005522431A (en) * | 2002-02-07 | 2005-07-28 | ジーティーエックス・インコーポレイテッド | Treatment of benign prostatic hyperplasia using SARM |
US6939872B2 (en) | 2001-05-30 | 2005-09-06 | Astrazeneca Ab | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
US6962914B2 (en) | 2001-04-27 | 2005-11-08 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
US6969714B2 (en) | 2000-09-05 | 2005-11-29 | Astrazeneca Ab | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
WO2006003440A1 (en) * | 2004-07-05 | 2006-01-12 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
WO2006044457A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
WO2006064251A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
US7105530B2 (en) | 2000-12-21 | 2006-09-12 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7141569B2 (en) | 2001-04-10 | 2006-11-28 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
US7153855B2 (en) | 2001-03-08 | 2006-12-26 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US7153964B2 (en) | 2000-03-01 | 2006-12-26 | Astrazeneca Ab | Pyrimidine compounds |
US7163940B2 (en) | 2000-12-15 | 2007-01-16 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US7176212B2 (en) | 1998-08-29 | 2007-02-13 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
US7186714B2 (en) | 2001-06-21 | 2007-03-06 | Smithkline Beecham Corporation | Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
WO2007036732A1 (en) * | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
US7223772B1 (en) | 1998-11-03 | 2007-05-29 | Smithkline Beecham Corporation | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
WO2008075353A1 (en) * | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
WO2008078091A1 (en) * | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
WO2008078100A2 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
US7427626B2 (en) | 2003-05-16 | 2008-09-23 | Astrazeneca Ab | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors |
WO2008150799A1 (en) * | 2007-06-01 | 2008-12-11 | Smithkline Beecham Corporation | Imidazopyridine kinase inhibitors |
WO2009047522A1 (en) | 2007-10-12 | 2009-04-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
WO2009071701A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
WO2010009155A2 (en) * | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
FR2933981A1 (en) * | 2008-07-18 | 2010-01-22 | Sanofi Aventis | New imidazo(1,2-a)pyridine derivatives are mesenchymal-epithelial transition protein kinase inhibitors useful in a pharmaceutical composition for preparing a medicament to treat/prevent e.g. fibrotic disorders, allergies and asthma |
US7655652B2 (en) | 2004-02-03 | 2010-02-02 | Astrazeneca Ab | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation |
US7691855B2 (en) | 2002-07-09 | 2010-04-06 | Novartis Ag | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
WO2010049731A1 (en) * | 2008-10-29 | 2010-05-06 | Astrazeneca Ab | Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
EP2258704A1 (en) * | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
EP2306836A1 (en) * | 2008-07-01 | 2011-04-13 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
WO2011101161A1 (en) * | 2010-02-18 | 2011-08-25 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
US8076354B2 (en) | 2007-10-12 | 2011-12-13 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
US8088771B2 (en) | 2008-07-28 | 2012-01-03 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene inhibitor compounds |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
US8258316B2 (en) | 2009-06-08 | 2012-09-04 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline HDAC inhibitor compounds |
US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
US8399462B2 (en) | 2006-12-08 | 2013-03-19 | Roche Palo Alto Llc | JNK modulators |
US8481531B2 (en) | 2009-04-15 | 2013-07-09 | Astex Therapeutics Ltd | Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use |
US8722687B2 (en) | 2009-04-15 | 2014-05-13 | Astex Therapeutics Ltd | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy |
US8796244B2 (en) | 2008-06-13 | 2014-08-05 | Astex Therapeutics Ltd | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
US9034311B2 (en) | 2011-08-01 | 2015-05-19 | Almirall, S.A. | Pyridin-2(1 H)-one derivatives as JAK inhibitors |
US9133200B2 (en) | 2010-11-26 | 2015-09-15 | Almirall, S.A. | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors |
US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
WO2018011673A3 (en) * | 2016-07-09 | 2018-04-19 | Kishor Prabhakar Kumbhar | 1, 3, 5-dioxazine derivatives, method of preparation and application thereof as sulfide scavenger |
US10428050B2 (en) | 2012-11-21 | 2019-10-01 | Ptc Therapeutics, Inc. | Substituted reverse pyrimidine Bmi-1 inhibitors |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
MXPA04007838A (en) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Nicotinamide derivates useful as p38 inhibitors. |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
RU2007119637A (en) * | 2004-10-28 | 2008-12-10 | Айрм Ллк (Bm) | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG WAY MODULATORS |
US7812022B2 (en) * | 2004-12-21 | 2010-10-12 | Glaxosmithkline Llc | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
CN1939910A (en) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | Amino-metadiazine compound and its salt, its preparation and pharmaceutical use |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
BRPI0609802A2 (en) * | 2005-05-20 | 2017-05-02 | Alantos Pharmaceuticals Holding Inc | compound, pharmaceutical composition and use of a compound |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
US20080280906A1 (en) * | 2005-07-30 | 2008-11-13 | David Andrews | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders |
CN101326182B (en) * | 2005-12-05 | 2011-09-28 | 史密丝克莱恩比彻姆公司 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
EP2041132A2 (en) * | 2006-07-06 | 2009-04-01 | Boehringer Ingelheim International GmbH | New compounds |
GB0625826D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
ES2637794T3 (en) * | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Imidazo [1,2-A] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
FR2925905B1 (en) * | 2008-01-02 | 2010-11-05 | Sanofi Aventis | 2-BENZOYL-IMIDAZO-1,2-α-PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2945806B1 (en) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | NOVEL IMIDAZO [1,2-A] PYRIDINE DERIVATIVES, PREPARATION METHOD, MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND USE IN PARTICULAR AS MET INHIBITORS |
JP2011528338A (en) * | 2008-07-18 | 2011-11-17 | サノフイ−アベンテイス | Novel imidazo [1,2-a] pyridine derivatives, process for their preparation, their use as pharmaceuticals, pharmaceutical compositions, and new uses, especially as MET inhibitors |
CN102482283A (en) * | 2009-08-28 | 2012-05-30 | 阵列生物制药公司 | Raf inhibitor compounds and methods of use thereof |
CN102596961B (en) | 2009-10-30 | 2015-12-02 | 詹森药业有限公司 | Imidazo [1,2-b] pyridazine derivatives and the purposes as PDE10 inhibitor thereof |
AR080754A1 (en) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS |
BR112013033375B1 (en) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivatives of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline, their use, pharmaceutical composition that comprises them, process of preparation thereof, sterile solution and intermediate compound |
AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
ES2607184T3 (en) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Phosphodiesterase 10 enzyme inhibitors |
CN104761544B (en) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | The selective depressant of the important mutant of clinic of EGFR tyrosine kinase |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
CN110684368A (en) * | 2019-10-24 | 2020-01-14 | 江苏亚邦染料股份有限公司 | Method for synthesizing disperse red 92 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO1996040143A1 (en) * | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659363A (en) | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
US4946956A (en) | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
CA2146333A1 (en) | 1992-10-05 | 1994-04-14 | Tomio Kimura | Pyrimidine compound |
CA2148931A1 (en) | 1993-10-01 | 1995-04-13 | Jurg Zimmermann | Pyrimidineamine derivatives and processes for the preparation thereof |
PL179417B1 (en) | 1993-10-01 | 2000-09-29 | Novartis Ag | Pharmacologically active derivatives of pyridine and methods of obtaining them |
PT672042E (en) | 1993-10-01 | 2006-08-31 | Novartis Ag | Pharmacologically active pyrimidineamine derivatives and processes for their preparation |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
DE69530989T2 (en) | 1994-08-13 | 2004-05-19 | Yuhan Corp. | NEW PYRIMID DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
ATE251141T1 (en) | 1995-03-10 | 2003-10-15 | Berlex Lab | BENZAMIDINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ANTI-COAGULANTS |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0889888A4 (en) | 1996-03-25 | 2003-01-08 | Smithkline Beecham Corp | Novel treatment for cns injuries |
WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
JP3418624B2 (en) | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | Substituted imidazoles having cytokine inhibitory activity |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU5147598A (en) | 1996-10-17 | 1998-05-11 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
DE69735675T2 (en) | 1996-12-09 | 2006-08-31 | Asahi Denka Kogyo K.K. | PROCESS FOR THE PRODUCTION OF ACYLOXYALKANSULFONIC ACIDS |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
DE19710435A1 (en) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
JP2002501532A (en) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | Novel angiogenesis inhibitors |
PL199893B1 (en) | 1997-06-12 | 2008-11-28 | Rhone Poulenc Rorer Ltd | Imidazolyl-cyclic acetals |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU9449398A (en) | 1997-10-10 | 1999-05-03 | Imperial College Innovations Ltd. | Use of csaidtm compounds for the management of uterine contractions |
AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
US6335340B1 (en) | 1997-12-19 | 2002-01-01 | Smithkline Beecham Corporation | compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
CA2321153A1 (en) | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
GB2334461B (en) | 1998-02-20 | 2002-01-23 | Bespak Plc | Inhalation apparatus |
WO1999050250A1 (en) | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
ATE336484T1 (en) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
DE69933680T2 (en) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
CZ2001959A3 (en) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidines functioning as kinase inhibitors |
EP1114053A1 (en) | 1998-09-18 | 2001-07-11 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
US6531477B1 (en) | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
WO2000026209A1 (en) | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
TR200102714T2 (en) | 1999-02-01 | 2002-01-21 | Cv Therapeutics, Inc. | Purine inhibitors of cyclin dependent kinase 2 and IkB - & |
GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6627633B2 (en) | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
EP1224185B1 (en) | 1999-10-27 | 2005-11-30 | Novartis AG | Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use |
HUP0203403A3 (en) | 1999-11-22 | 2004-01-28 | Smithkline Beecham Plc | New imidazole derivatives, pharmaceutical compositions containing them and their use |
EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
WO2001060816A1 (en) | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
-
1999
- 1999-08-21 GB GBGB9919778.2A patent/GB9919778D0/en not_active Ceased
-
2000
- 2000-08-15 MX MXPA02001674A patent/MXPA02001674A/en active IP Right Grant
- 2000-08-15 US US10/069,019 patent/US6855719B1/en not_active Expired - Fee Related
- 2000-08-15 AT AT00953319T patent/ATE251623T1/en not_active IP Right Cessation
- 2000-08-15 CA CA002376293A patent/CA2376293A1/en not_active Abandoned
- 2000-08-15 BR BR0013476-7A patent/BR0013476A/en not_active Application Discontinuation
- 2000-08-15 NZ NZ516740A patent/NZ516740A/en unknown
- 2000-08-15 RU RU2002107128/04A patent/RU2248976C2/en not_active IP Right Cessation
- 2000-08-15 UA UA2002032241A patent/UA73522C2/en unknown
- 2000-08-15 HU HU0202494A patent/HUP0202494A3/en unknown
- 2000-08-15 PT PT00953319T patent/PT1214318E/en unknown
- 2000-08-15 DK DK00953319T patent/DK1214318T3/en active
- 2000-08-15 EE EEP200200080A patent/EE04964B1/en not_active IP Right Cessation
- 2000-08-15 AU AU65833/00A patent/AU757639B2/en not_active Ceased
- 2000-08-15 CZ CZ2002617A patent/CZ2002617A3/en unknown
- 2000-08-15 PL PL364722A patent/PL199615B1/en not_active IP Right Cessation
- 2000-08-15 ES ES00953319T patent/ES2208397T3/en not_active Expired - Lifetime
- 2000-08-15 DE DE60005850T patent/DE60005850T2/en not_active Expired - Lifetime
- 2000-08-15 IL IL14775200A patent/IL147752A0/en active IP Right Grant
- 2000-08-15 SK SK240-2002A patent/SK287033B6/en not_active IP Right Cessation
- 2000-08-15 KR KR1020027002240A patent/KR100737259B1/en not_active IP Right Cessation
- 2000-08-15 WO PCT/GB2000/003139 patent/WO2001014375A1/en active IP Right Grant
- 2000-08-15 CN CNB008118264A patent/CN1174981C/en not_active Expired - Fee Related
- 2000-08-15 JP JP2001518706A patent/JP4280442B2/en not_active Expired - Fee Related
- 2000-08-15 EP EP00953319A patent/EP1214318B1/en not_active Expired - Lifetime
- 2000-08-17 CO CO00061949A patent/CO5460265A1/en not_active Application Discontinuation
- 2000-08-18 MY MYPI20003812 patent/MY123390A/en unknown
- 2000-08-18 AR ARP000104309A patent/AR031075A1/en not_active Application Discontinuation
-
2002
- 2002-01-02 ZA ZA200200028A patent/ZA200200028B/en unknown
- 2002-01-21 IL IL147752A patent/IL147752A/en not_active IP Right Cessation
- 2002-02-04 BG BG106383A patent/BG65566B1/en unknown
- 2002-02-15 IS IS6274A patent/IS2068B/en unknown
- 2002-02-20 NO NO20020832A patent/NO322818B1/en not_active IP Right Cessation
- 2002-09-25 HK HK02107002.9A patent/HK1045510B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO1996040143A1 (en) * | 1995-06-07 | 1996-12-19 | Smithkline Beecham Corporation | Imidazole compounds |
Cited By (149)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451794B1 (en) | 1997-09-05 | 2002-09-17 | Smithkline Beecham Corporation | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors |
US6861429B2 (en) | 1997-09-05 | 2005-03-01 | Smithkline Beecham Corporation | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
US6831097B2 (en) | 1997-09-05 | 2004-12-14 | Smithkline Beecham Corporation | 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
US7176212B2 (en) | 1998-08-29 | 2007-02-13 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
US6632820B1 (en) | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
US7223772B1 (en) | 1998-11-03 | 2007-05-29 | Smithkline Beecham Corporation | Pyrazolopyridine derivatives as selective cox-2 inhibitors |
US6593326B1 (en) | 1998-12-24 | 2003-07-15 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
US6716831B1 (en) | 1999-03-06 | 2004-04-06 | Astrazeneca Ab | 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity |
US6670368B1 (en) | 1999-04-06 | 2003-12-30 | Astrazeneca Ab | Pyrimidine compounds with pharmaceutical activity |
US6803463B2 (en) | 1999-12-22 | 2004-10-12 | Smithkline Beecham Corporation | Process for the preparation of pyrazolopyridine derivatives |
JP2003532635A (en) * | 2000-02-17 | 2003-11-05 | アムジエン・インコーポレーテツド | Kinase inhibitors |
US6838464B2 (en) | 2000-03-01 | 2005-01-04 | Astrazeneca Ab | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
US7067522B2 (en) | 2000-03-01 | 2006-06-27 | Astrazeneca Ab | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
US6649608B2 (en) | 2000-03-01 | 2003-11-18 | Astrazeneca Ab | 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents |
US7153964B2 (en) | 2000-03-01 | 2006-12-26 | Astrazeneca Ab | Pyrimidine compounds |
US6710052B2 (en) | 2000-03-01 | 2004-03-23 | Astrazeneca | Pyrimidine compounds |
US6906065B2 (en) | 2000-03-28 | 2005-06-14 | Astrazeneca Ab | 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
US6908920B2 (en) | 2000-07-11 | 2005-06-21 | Astrazeneca Ab | Pyrimidine derivatives |
WO2002016359A1 (en) * | 2000-08-22 | 2002-02-28 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
US6969714B2 (en) | 2000-09-05 | 2005-11-29 | Astrazeneca Ab | Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
EP1349841B1 (en) * | 2000-12-06 | 2009-12-02 | Signal Pharmaceuticals, LLC | Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
US7442699B2 (en) | 2000-12-06 | 2008-10-28 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7160897B2 (en) | 2000-12-15 | 2007-01-09 | Smithkline Beecham Corporation | Therapeutic compounds |
US7163940B2 (en) | 2000-12-15 | 2007-01-16 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US6919352B2 (en) | 2000-12-15 | 2005-07-19 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
US7087618B2 (en) | 2000-12-15 | 2006-08-08 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US8114885B2 (en) | 2000-12-21 | 2012-02-14 | Glaxosmithkline Llc | Chemical compounds |
US7262203B2 (en) | 2000-12-21 | 2007-08-28 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
US7858626B2 (en) | 2000-12-21 | 2010-12-28 | Glaxosmithkline Llc | Pyrimidineamines as angiogenesis modulators |
US7105530B2 (en) | 2000-12-21 | 2006-09-12 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
KR100829035B1 (en) * | 2001-02-17 | 2008-05-16 | 아스트라제네카 아베 | Pyrimidine derivatives for inhibition of cell-proliferation |
US6844341B2 (en) | 2001-02-17 | 2005-01-18 | Astrazeneca Ab | Pyrimidine derivatives for inhibition of cell proliferation |
WO2002066481A1 (en) * | 2001-02-17 | 2002-08-29 | Astrazeneca Ab | Pyrimidine derivatives for inhibition of cell-proliferation |
WO2002065979A3 (en) * | 2001-02-20 | 2003-02-20 | Astrazeneca Ab | (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
US7078410B2 (en) | 2001-02-20 | 2006-07-18 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders |
WO2002066480A2 (en) * | 2001-02-20 | 2002-08-29 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
WO2002066480A3 (en) * | 2001-02-20 | 2004-04-01 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
US7345050B2 (en) | 2001-02-20 | 2008-03-18 | Astrazeneca Ab | Pyrimidine compounds |
US7153855B2 (en) | 2001-03-08 | 2006-12-26 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyrimidine therapeutic compounds |
US7109209B2 (en) | 2001-03-30 | 2006-09-19 | Smithkline Beecham Corporation | Pyrazolopyridines, process for their preparation and use as therapeutic compounds |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
WO2002083675A3 (en) * | 2001-04-10 | 2002-12-05 | Merck Sharp & Dohme | Inhibitors of akt activity |
US7141569B2 (en) | 2001-04-10 | 2006-11-28 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
WO2002083675A2 (en) * | 2001-04-10 | 2002-10-24 | Merck Sharp & Dohme Limited | Inhibitors of akt activity |
US6962914B2 (en) | 2001-04-27 | 2005-11-08 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
US6756498B2 (en) | 2001-04-27 | 2004-06-29 | Smithkline Beecham Corporation | Process for the preparation of chemical compounds |
US7030134B2 (en) | 2001-04-27 | 2006-04-18 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
WO2002096888A1 (en) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US6939872B2 (en) | 2001-05-30 | 2005-09-06 | Astrazeneca Ab | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
US7186714B2 (en) | 2001-06-21 | 2007-03-06 | Smithkline Beecham Corporation | Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
WO2003031446A1 (en) * | 2001-10-05 | 2003-04-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
US7244740B2 (en) | 2001-10-05 | 2007-07-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
WO2003050120A1 (en) * | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
US7199120B2 (en) | 2001-12-11 | 2007-04-03 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
WO2003051886A1 (en) * | 2001-12-17 | 2003-06-26 | Smithkline Beecham Corporation | Pyrazolopyridazine derivatives |
US7279473B2 (en) | 2001-12-17 | 2007-10-09 | Smithkline Beecham Corporation | Pyrazolopyridazine derivatives |
JP2005522431A (en) * | 2002-02-07 | 2005-07-28 | ジーティーエックス・インコーポレイテッド | Treatment of benign prostatic hyperplasia using SARM |
US7485638B2 (en) | 2002-03-09 | 2009-02-03 | Astrazeneca Ab | Pyrimidine compounds |
US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
WO2003076433A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | Pyrimidine compounds |
WO2003076434A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
WO2003076435A1 (en) * | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | Pyrimidine compounds |
US7446105B2 (en) | 2002-03-09 | 2008-11-04 | Astrazeneca Ab | Pyrimidine compounds |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
US7691855B2 (en) | 2002-07-09 | 2010-04-06 | Novartis Ag | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives |
US7153863B2 (en) | 2002-10-03 | 2006-12-26 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridline derivatives |
WO2004033454A1 (en) * | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
US7427626B2 (en) | 2003-05-16 | 2008-09-23 | Astrazeneca Ab | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors |
WO2004101564A1 (en) * | 2003-05-16 | 2004-11-25 | Astrazeneca Ab | Pyrimidine derivatives possessing cell-cycle inhibitory activity |
US7579344B2 (en) | 2003-05-16 | 2009-08-25 | Astrazeneca Ab | Pyrimidine derivatives possessing cell-cycle inhibitors activity |
US7655652B2 (en) | 2004-02-03 | 2010-02-02 | Astrazeneca Ab | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation |
WO2006003440A1 (en) * | 2004-07-05 | 2006-01-12 | Astex Therapeutics Limited | 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors |
US7799915B2 (en) | 2004-10-13 | 2010-09-21 | Wyeth Llc | Anilino-pyrimidine analogs |
WO2006044457A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
EP2258704A1 (en) * | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
US8178672B2 (en) | 2004-10-19 | 2012-05-15 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
AU2005315392B2 (en) * | 2004-12-17 | 2010-03-11 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors |
WO2006064251A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
WO2007036732A1 (en) * | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
US9725694B2 (en) | 2005-12-29 | 2017-08-08 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
US8399462B2 (en) | 2006-12-08 | 2013-03-19 | Roche Palo Alto Llc | JNK modulators |
US9422235B2 (en) | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
WO2008075353A1 (en) * | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
US8513276B2 (en) | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
WO2008078091A1 (en) * | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
WO2008078100A2 (en) | 2006-12-22 | 2008-07-03 | Astex Therapeutics Limited | Tricyclic amine derivatives as protein tyrosine kinase inhibitors |
US8440822B2 (en) | 2007-04-18 | 2013-05-14 | Michael Joseph Luzzio | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8247411B2 (en) | 2007-04-18 | 2012-08-21 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US10450297B2 (en) | 2007-04-18 | 2019-10-22 | Pfizer, Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
RU2469036C2 (en) * | 2007-06-01 | 2012-12-10 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Imidazopyridine kinase inhibitors |
WO2008150799A1 (en) * | 2007-06-01 | 2008-12-11 | Smithkline Beecham Corporation | Imidazopyridine kinase inhibitors |
US8093239B2 (en) | 2007-06-01 | 2012-01-10 | Glaxosmithkline Llc | Imidazopyridine kinase inhibitors |
US8076354B2 (en) | 2007-10-12 | 2011-12-13 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
US8859582B2 (en) | 2007-10-12 | 2014-10-14 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
WO2009047522A1 (en) | 2007-10-12 | 2009-04-16 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
US8071614B2 (en) | 2007-10-12 | 2011-12-06 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
US8859583B2 (en) | 2007-10-12 | 2014-10-14 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
WO2009071701A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
EA018459B1 (en) * | 2007-12-07 | 2013-08-30 | Новартис Аг | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
US8367687B2 (en) | 2007-12-07 | 2013-02-05 | Novartis Ag | Pyrazole derivatives |
US8796244B2 (en) | 2008-06-13 | 2014-08-05 | Astex Therapeutics Ltd | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases |
EP2306836A4 (en) * | 2008-07-01 | 2011-12-21 | Ptc Therapeutics Inc | Bmi-1 protein expression modulators |
EP2306836A1 (en) * | 2008-07-01 | 2011-04-13 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
US8680113B2 (en) | 2008-07-01 | 2014-03-25 | Ptc Therapeutics, Inc. | BMI-1 protein expression modulators |
US8344018B2 (en) | 2008-07-14 | 2013-01-01 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
WO2010009155A3 (en) * | 2008-07-14 | 2010-09-23 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
WO2010009155A2 (en) * | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Fused heterocyclyc inhibitor compounds |
FR2933981A1 (en) * | 2008-07-18 | 2010-01-22 | Sanofi Aventis | New imidazo(1,2-a)pyridine derivatives are mesenchymal-epithelial transition protein kinase inhibitors useful in a pharmaceutical composition for preparing a medicament to treat/prevent e.g. fibrotic disorders, allergies and asthma |
US8088771B2 (en) | 2008-07-28 | 2012-01-03 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene inhibitor compounds |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
WO2010049731A1 (en) * | 2008-10-29 | 2010-05-06 | Astrazeneca Ab | Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
US8481531B2 (en) | 2009-04-15 | 2013-07-09 | Astex Therapeutics Ltd | Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use |
US8722687B2 (en) | 2009-04-15 | 2014-05-13 | Astex Therapeutics Ltd | Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy |
US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
US8258316B2 (en) | 2009-06-08 | 2012-09-04 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline HDAC inhibitor compounds |
AU2011217489B2 (en) * | 2010-02-18 | 2015-09-03 | Almirall, S.A. | Pyrazole derivatives as JAK inhibitors |
WO2011101161A1 (en) * | 2010-02-18 | 2011-08-25 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
US9206183B2 (en) | 2010-02-18 | 2015-12-08 | Almirall, S.A. | Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
US9133200B2 (en) | 2010-11-26 | 2015-09-15 | Almirall, S.A. | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors |
US9034311B2 (en) | 2011-08-01 | 2015-05-19 | Almirall, S.A. | Pyridin-2(1 H)-one derivatives as JAK inhibitors |
US10428050B2 (en) | 2012-11-21 | 2019-10-01 | Ptc Therapeutics, Inc. | Substituted reverse pyrimidine Bmi-1 inhibitors |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
EP3039015A4 (en) * | 2013-08-30 | 2017-01-11 | PTC Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
US10370371B2 (en) | 2013-08-30 | 2019-08-06 | Ptc Therapeutics, Inc. | Substituted pyrimidine Bmi-1 inhibitors |
WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
WO2018011673A3 (en) * | 2016-07-09 | 2018-04-19 | Kishor Prabhakar Kumbhar | 1, 3, 5-dioxazine derivatives, method of preparation and application thereof as sulfide scavenger |
US11053232B2 (en) | 2016-07-09 | 2021-07-06 | Kishor Prabhakar Kumbhar | 1,3,5-dioxazine derivatives, method of preparation and application thereof as sulfide scavenger |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1214318B1 (en) | Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives | |
EP1268445B1 (en) | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases | |
AU2002231960A1 (en) | Pyrimidine derivatives for inhibition of cell-proliferation | |
WO2002066481A1 (en) | Pyrimidine derivatives for inhibition of cell-proliferation | |
AU2001239414A1 (en) | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases | |
ZA200300079B (en) | Pyrimidine derivatives. | |
EP1934213A1 (en) | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity | |
US7427626B2 (en) | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors | |
US7579344B2 (en) | Pyrimidine derivatives possessing cell-cycle inhibitors activity | |
JP2005524672A (en) | Imidazolyl-substituted pyrimidine derivatives having CDK inhibitory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000953319 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2376293 Country of ref document: CA Ref document number: 2376293 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200200028 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65833/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/00027/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 147752 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 516740 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2000 106383 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/001674 Country of ref document: MX Ref document number: 2402002 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-617 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008118264 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027002240 Country of ref document: KR Ref document number: 10069019 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027002240 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002107128 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-617 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2000953319 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 65833/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000953319 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 516740 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 516740 Country of ref document: NZ |